Loading...
•
Sep 30, 2021
Edgewise Therapeutics Q3 2021 Earnings Report
Edgewise Therapeutics reported financial results for the third quarter 2021 and recent business highlights.
Key Takeaways
Edgewise Therapeutics reported a net loss of $12.9 million for Q3 2021. The company's cash and marketable securities totaled $290 million as of September 30, 2021. They announced positive topline results from the EDG-5506 Phase 1 MAD study.
Announced positive topline results from the EDG-5506 Phase 1 multiple ascending dose (MAD) study in healthy volunteers (HV)
Dosed first Becker muscular dystrophy (BMD) patients with EDG-5506 as part of the ongoing Phase 1b trial
Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) expected to start in 2022
Cash and marketable securities of $290 million as of September 30, 2021
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...